Legend Biotech Corp
NASDAQ:LEGN
Legend Biotech Corp
Revenue
Legend Biotech Corp
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Legend Biotech Corp
NASDAQ:LEGN
|
Revenue
$285.1m
|
CAGR 3-Years
56%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Legend Biotech Corp's Revenue?
Revenue
285.1m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Revenue amounts to 285.1m USD.
What is Legend Biotech Corp's Revenue growth rate?
Revenue CAGR 5Y
42%
Over the last year, the Revenue growth was 144%. The average annual Revenue growth rates for Legend Biotech Corp have been 56% over the past three years , 42% over the past five years .